SCHEDULE 13G: The Hewlett Fund LP Discloses Significant 8.255% Stake in Plus Therapeutics, Inc.

The Hewlett Fund LP has disclosed a beneficial ownership of 8.255% in Plus Therapeutics, Inc., holding 2,006,552 shares of common stock.

Summary

• The Hewlett Fund LP has filed a Schedule 13G with the SEC, reporting its beneficial ownership in Plus Therapeutics, Inc.
• The fund beneficially owns 2,006,552 shares of Plus Therapeutics, Inc. common stock.
• This ownership represents 8.255% of the company's total outstanding common stock.
• The percentage is calculated based on 24,307,166 shares of Plus Therapeutics, Inc. common stock outstanding as of May 19, 2025.
• The Hewlett Fund LP holds sole voting power and sole dispositive power over all 2,006,552 shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive investment by an institutional fund, which can be viewed as a positive signal of confidence in the issuer, Plus Therapeutics, Inc., although it provides no operational or financial performance details.

Positives

• A significant institutional investor, The Hewlett Fund LP, has taken an 8.255% stake in Plus Therapeutics, Inc., which may signal confidence in the company's long-term prospects.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Plus Therapeutics, Inc.'s future performance or strategic direction, as it is a passive ownership disclosure.

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G filing indicates a significant passive investment by an institutional fund, a common occurrence in the public markets as funds build positions in companies they believe have long-term value. It reflects a specific investment decision by The Hewlett Fund LP rather than a broad industry trend.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may provide increased confidence and potentially contribute to share price stability or appreciation.

Key Dates

Keywords

Plus Therapeutics, The Hewlett Fund LP, Schedule 13G, beneficial ownership, common stock, institutional investment, equity stake, SEC filing